Tempus Law Associates and CAM advises in Aryastha Life Sciences Series A funding from Vessella Group

Aryastha Life Sciences, a leading Contract Research and Development Organization in healthcare, has achieved a major milestone by successfully concluding its Series A funding with significant backing from Vessella Group, a prominent investor in India.

Tempus Law Associates and Cyril Amarchand Mangaldas structured the business legally. While specific Series A terms remain undisclosed, Aryastha's partnership with Vessella promises innovation and quality healthcare services worldwide."

Vessella Group, a renowned and distinguished investor in many sectors including infrastructure, healthcare and expands into pharma and life sciences, affirming a dedication to global healthcare progress. Visit www.vessella.com for details.

Aryastha, an innovation-driven Life Science service provider, offers CRDMO solutions for novel drug development from Hyderabad, India. With advanced R&D and a visionary approach, Aryastha excels in Pharmaceuticals and Biotechs.

Read More: https://www.prnewswire.com/in/news-releases/aryastha-life-sciences-secures-series-a-funding-from-vessella-group-301912329.html